Skip to main content
. Author manuscript; available in PMC: 2018 Aug 23.
Published in final edited form as: JCO Precis Oncol. 2018 Jul 13;2018:10.1200/PO.17.00235. doi: 10.1200/PO.17.00235

Fig 4.

Fig 4.

Genomic co-alterations associated with MDM2 amplification (n = 3,650). The most common co-alterations associated with MDM2 amplification were CDK4 (43.6% [1,591 of 3,650]), FRS2 (40.8% [1,491 of 3,650]), TP53 (20.1% [733 of 3,650]), CDKN2A (18.2% [665 of 3,650]), and EGFR (12.7% [462 of 3,650]; Data Supplement).